A genomic analysis of lung cancer in people with no history of smoking has found that a majority of these tumors arise from the accumulation of mutations caused by natural processes in the body. This study was conducted by an international team led by researchers at the National Cancer Institute (NCI) and describes for the first time three molecular subtypes of lung cancer in never-smokers. Their findings were published by Zhang et al in Nature Genetics.
“What we’re seeing is that there are different subtypes of lung cancer in never-smokers that have distinct molecular characteristics and evolutionary processes,” said corresponding study author and epidemiologist Maria Teresa Landi, MD, PhD, of the Integrative Tumor Epidemiology Branch in NCI’s Division of Cancer Epidemiology and Genetics. “In the future, we may be able to have different treatments based on these subtypes.”
More on Lung Cancer in Never-Smokers
Lung cancer is the leading cause of cancer-related deaths worldwide; every year, more than 2 million people are diagnosed with the disease globally. Most people who develop lung cancer have a history of tobacco smoking, but 10% to 20% of people who develop lung cancer have never smoked. Lung cancer in never-smokers occurs more frequently in women and at an earlier age than lung cancer in smokers.
Environmental risk factors, such as exposure to secondhand tobacco smoke, radon, air pollution, and asbestos, or having had previous lung diseases, may explain some lung cancers among never-smokers, but scientists still don’t know what causes the majority of these cancers.
What we’re seeing is that there are different subtypes of lung cancer in never-smokers that have distinct molecular characteristics and evolutionary processes. In the future, we may be able to have different treatments based on these subtypes.— Maria Teresa Landi, MD, PhD
Tweet this quote
Current Analysis Methods
In this large epidemiologic study, researchers used whole-genome sequencing to characterize the genomic changes in tumor tissue and matched normal tissue from 232 never-smokers, predominantly of European descent, who had been diagnosed with non–small cell lung cancer. The tumors included 189 adenocarcinomas, 36 carcinoids, and 7 other tumors of various types. The patients had not yet undergone treatment for their cancer. The researchers then combed the tumor genomes for mutational signatures.
In this study, the researchers discovered that a majority of the tumor genomes of never-smokers bore mutational signatures associated with damage from endogenous processes.
As expected, because the study was limited to never-smokers, the researchers did not find any mutational signatures that have previously been associated with direct exposure to tobacco smoking, nor did they find those signatures among the 62 patients who had been exposed to secondhand tobacco smoke. However, Dr. Landi cautioned that the sample size was small and the level of exposure highly variable.
“We need a larger sample size with detailed information on exposure to really study the impact of secondhand tobacco smoking on the development of lung cancer in never-smokers,” Dr. Landi said.
The genomic analyses also revealed three novel subtypes of lung cancer in never-smokers, to which the researchers assigned musical names based on the level of “noise” (that is, the number of genomic changes) in the tumors. The predominant “piano” subtype had the fewest mutations; it appeared to be associated with the activation of progenitor cells. This subtype of tumor grows extremely slowly, over many years, and is difficult to treat because it can have many different driver mutations. The “mezzo-forte” subtype had specific chromosomal changes as well as mutations in the growth factor receptor gene EGFR, which is commonly altered in lung cancer, and exhibited faster tumor growth. The “forte” subtype exhibited whole-genome doubling, a genomic change that is often seen in lung cancers in smokers; this subtype of tumor also grows quickly.
“We’re starting to distinguish subtypes that could potentially have different approaches for prevention and treatment,” said Dr. Landi. For example, the slow-growing piano subtype could give clinicians a window of opportunity to detect these tumors earlier, when they are less difficult to treat. In contrast, the mezzo-forte and forte subtypes have only a few major driver mutations, suggesting that these tumors could be identified by a single biopsy and could benefit from targeted treatments, she said.
A future direction of this research will be to study people of different ethnic backgrounds and geographic locations, and whose exposure history to lung cancer risk factors is well described.
“We’re at the beginning of understanding how these tumors evolve,” Dr. Landi said. “This analysis shows that there is heterogeneity, or diversity, in lung cancers in never-smokers.”
Disclosure: The study was conducted by the Intramural Research Program of NCI and National Institute of Environmental Health Sciences. For full disclosures of the study authors, visit nature.com.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.